Search results
Apr 18, 2023 · A preliminary randomized placebo-controlled clinical trial (SLCTR/2014/023) testing efficacy of rupatadine for acute dengue patients revealed improved platelet counts, reduction in liver transaminases suggesting reduced tissue inflammation, and reduction in volume of plural effusions on certain days of the study protocol in their post hoc ...
- Figure - PMC - National Center for Biotechnology Information
Dengue viruses (DENV) continue to circulate worldwide,...
- Table - PMC - National Center for Biotechnology Information
Randomized double-blind placebo-controlled trial ... and...
- Management of Dengue: An Updated Review - PMC
Khan Assir MZ, Kamran U, Ahmad HI, et al. Effectiveness of...
- Current Status of Dengue Therapeutics Research and ...
These trials have all used the conventional double-blinded,...
- Figure - PMC - National Center for Biotechnology Information
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial - The Lancet Global Health. Articles | Volume 12, ISSUE 2, e257-e270, February 2024. Download Full Issue.
People also ask
How effective is dengue treatment against hospitalised virologically confirmed dengue?
Which drugs are used in clinical trials for dengue?
How is severe dengue managed?
Nov 6, 2019 · Methods. We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial of a tetravalent dengue vaccine candidate (TAK-003) in regions of Asia and Latin America in which...
- Shibadas Biswal, Humberto Reynales, Xavier Saez-Llorens, Pio Lopez, Charissa Borja-Tabora, Pope Kosa...
- 2019
Sep 24, 2015 · A recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) has been assessed in two phase 3 randomized efficacy trials involving more than 31,000 children between the ages of 2 and...
- Hadinegoro, Arredondo-García Jl, Capeding Mr, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Isma...
- 2015
Apr 12, 2012 · The establishment of a therapeutic pipeline and the design of randomized, controlled trials of drugs targeting the virus or the immune response are recent developments.